Use of BIP-Needles in Rheumatologic Injections
INJ-INAR-01 Use of BIP-Needles in Rheumatologic Injections
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
HUS
-
Helsinki, HUS, Finland, FI-00029
- Helsinki University Hospital, Clinic of Rheumathology
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Adult patients having an inflammatory rheumatic disease requiring an intra-articular glucocorticoid injection.
Exclusion Criteria:
- Exclusion criteria are the same as generally for intra-articular glucocorticoid injections (e.g. bacterial infection or recent surgical operation relating the joint).
- In addition for not giving (or not capable to give) the consent personally for any reason is an absolute exclusion criterion.
- In addition pregnant women are excluded
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: BIP Needle
Injeq Bioimpedance Probe (BIP) Needle is an injection needle that has bioimpedance measurement capability.
It measures bioimpedance and detects synovial fluid during inta-articular injection.
|
Injeq Bioimpedance Probe (BIP) Needle is an injection needle that has bioimpedance measurement capability.
It consists of traditional needle cannulae and removable bioimpedance probe which enables the measurement of bioimpedance.
The needle is connected to measurement device and tissue identifying algorithm.
Bioimpedance is measured during the operation and the algorithm detects when the needle tip is in contact with synovial fluid.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
True Positive Detection of Synovial Fluid Marked in Case Report Form
Time Frame: During intra-articular injection
|
Measurement device indicates with a sound and visual feedback when needle is in contact with synovial fluid.
Physician verifies the location with ultrasound imaging, aspiration of synovial fluid and/or lack of resistance in glucocorticoid injection.
Even if the device does not detect the synovial fluid, physician performs the injection when needed.
Physician marks to the case report form whether the device provided detections during the puncture and were the detections true or false detections.
|
During intra-articular injection
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Riitta Luosujärvi, PhD MD, Helsinki University Hospital, Clinic of Rheumathology
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
Other Study ID Numbers
- INJ-INAR-01
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.